AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 211 min read$ARQT

Burnett Patrick sold $46K of ARQT

Burnett Patrick (See Remarks) sold 1,697 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $27.00 on 2026-08-19.

Original reporting
SEC EDGAR · Burnett Patrick
Published Aug 21, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
low confidence
Mentioned
$ARQT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to affect ARQT's share price materially.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical data or regulatory events not disclosed in the filing.

Relevance 3/10Novelty 4/10Timing: today

Background

Form 4 filings disclose insider transactions; traders monitor them for signals.

Company-level read

Ticker impact

$ARQTNeutralLow confidence
Context

Officer Burnett Patrick sold 1,697 shares of Arcutis Biotherapeutics for $45,819 in a Form 4 filing.

Expected impact

minimal impact; price likely unchanged

Evidence & confidence

The sale represents less than 1.5% of the insider's remaining stake and is under $50k, unlikely to move the market.

Market effects

Sector

None; biotech sector not affected by a single small insider sale.

Regional

None; the filing is U.S.-based with no broader regional effect.

Global

None; no global market relevance.

Counterpoint

What could challenge this read

The insider may be diversifying without negative outlook; could be neutral or positive for the stock.

Key entities

  • Company
    Arcutis Biotherapeutics, Inc.

    Biotech firm developing dermatology therapies.

  • Officer
    Burnet Patrick

    Company officer who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARQT insider trading history →

Related articles

AUG 5
$ARQTHigh

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update • Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand grow

SEC EDGAR 8-K6 min
JUL 8
$ARQTMedAI 8/10

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Arcutis Biotherapeutics (Nasdaq: ARQT) said the FDA accepted its supplemental NDA for ZORYVE (roflumilast) cream 0.05% to expand use for mild to moderate atopic dermatitis in infants aged 3 to 24 months. The FDA set a PDUFA target action date of Feb. 23, 2027. Data cited include Phase 2 INTEGUMENT-INFANT (101 infants) and Phase 1 PK (19 infants).

manilatimes.net5 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min